Christine Lovly Archives
Feb. 13, 2020—An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.
Apr. 11, 2019—When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.
Feb. 28, 2019—A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.
Aug. 2, 2018—During the August Leadership Assembly at Vanderbilt University Medical Center, patients whose lives have been restored through personalized care shared their emotional stories, illustrating the Medical Center’s longtime commitment to use the latest advancements in genomic medicine as a powerful tool to tailor care to the individual.
Jun. 14, 2018—A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.
Mar. 8, 2018—Christine Lovly, MD, PhD, assistant professor of Medicine at Vanderbilt, has received a $200,000 grant to support promising new research on lung cancer.
Nov. 2, 2017—Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC).
Sep. 28, 2017—A trio of Vanderbilt University scientists described their cutting-edge investigations of cellular dynamics and cancer treatment during last week’s Flexner Discovery Lecture.
Sep. 14, 2017—Three Vanderbilt University scientists on the forefront of research in cellular dynamics and cancer treatment will discuss their cutting-edge investigations during the next Flexner Discovery Lecture on Thursday, Sept. 21.
May. 4, 2017—Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI).
Apr. 24, 2017— Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt University Medical Center (VUMC), has been elected to The American Society for Clinical Investigation (ASCI). The ASCI is an elite honor society of physician-scientists. The Society, founded in 1908, is home to nearly 3,000 members from the upper ranks of academic...
Oct. 20, 2016—Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.